Pharma Focus Asia

Coya Therapeutics Announces Agreement with Dr. Reddy’s Laboratories

Tuesday, March 21, 2023

Coya Therapeutics announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. Under the terms of the Agreement, Coya has been granted an exclusive, royalty-bearing licence to Dr. Reddy’s proposed biosimilar Abatacept for the development and commercialisation of Coya 302 for the treatment of certain neurological diseases for sale in multiple territories including North and South America, the EU, United Kingdom, and Japan.

The Agreement also provides for the licence of Coya 301, Coya’s low dose IL-2 to Dr. Reddy’s to permit the commercialisation by Dr. Reddy’s of Coya 302 in territories not otherwise granted to Coya. With this partnership, both the organisations will strengthen their abilities to deliver this treatment to patients with neurodegenerative diseases, once regulatory approval is granted.

COYA 302 is an investigational combination biologic for subcutaneous administration, comprised of COYA 301 and CTLA4-Ig (Abatacept). COYA 302 has a dual mechanism of action intended to suppress the chronic and sustained inflammation underlying certain neurodegenerative diseases.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024